Elimination of tumorigenic pluripotent stem cells from their differentiated cell therapy products: An important step toward ensuring safe cell therapy.

IF 5.9 2区医学 Q1 CELL & TISSUE ENGINEERING

Stem Cell Reports Pub Date : 2025-07-08 Epub Date: 2025-06-19 DOI:10.1016/j.stemcr.2025.102543

Afsaneh Yazdani Movahed, Rana Bagheri, Pierre Savatier, Tomo Šarić, Sharif Moradi

引用次数: 0

Abstract

Human pluripotent stem cells (hPSCs) are considered a promising tool for regenerative medicine due to their unique self-renewal and multi-lineage differentiation capabilities. Although over 100 clinical trials have employed hPSC-derived products to treat life-threatening diseases, the tumorigenic risk posed by residual undifferentiated hPSCs remains a formidable obstacle to their clinical implementation. In this review, we summarize current strategies to eliminate tumorigenic hPSCs, most of which target hPSC-specific markers, and critically evaluate the advantages and limitations of each approach. Finally, we discuss various methods that can be used to evaluate the efficiency of pluripotent stem cell (PSC) elimination.

查看原文本刊更多论文

从分化细胞治疗产品中去除致瘤性多能干细胞：确保细胞治疗安全的重要一步。

人类多能干细胞（hPSCs）由于其独特的自我更新和多谱系分化能力而被认为是再生医学的一个有前途的工具。尽管已有超过100项临床试验使用hPSCs衍生产品治疗危及生命的疾病，但残留的未分化hPSCs所带来的致瘤风险仍然是其临床应用的巨大障碍。在这篇综述中，我们总结了目前消除致瘤性hPSCs的策略，其中大多数针对hpsc特异性标记物，并批判性地评估了每种方法的优点和局限性。最后，我们讨论了可用于评估多能干细胞（PSC）消除效率的各种方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Stem Cell Reports CELL & TISSUE ENGINEERING-CELL BIOLOGY

CiteScore

10.50

自引率

1.70%

发文量

200

审稿时长

28 weeks

期刊介绍： Stem Cell Reports publishes high-quality, peer-reviewed research presenting conceptual or practical advances across the breadth of stem cell research and its applications to medicine. Our particular focus on shorter, single-point articles, timely publication, strong editorial decision-making and scientific input by leaders in the field and a "scoop protection" mechanism are reasons to submit your best papers.